168 related articles for article (PubMed ID: 24403012)
21. Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge.
Wang L; Goschnick MW; Coppel RL
Infect Immun; 2004 Oct; 72(10):6172-5. PubMed ID: 15385527
[TBL] [Abstract][Full Text] [Related]
22. Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-gamma-dependent responses induced by vaccination and/or challenge infection.
Petritus PM; Burns JM
J Immunol; 2008 Jan; 180(1):444-53. PubMed ID: 18097046
[TBL] [Abstract][Full Text] [Related]
23. Production, characterisation and immunogenicity of a plant-made Plasmodium antigen--the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1.
Ma C; Wang L; Webster DE; Campbell AE; Coppel RL
Appl Microbiol Biotechnol; 2012 Apr; 94(1):151-61. PubMed ID: 22170105
[TBL] [Abstract][Full Text] [Related]
24. Absolute requirement for an active immune response involving B cells and Th cells in immunity to Plasmodium yoelii passively acquired with antibodies to the 19-kDa carboxyl-terminal fragment of merozoite surface protein-1.
Hirunpetcharat C; Vukovic P; Liu XQ; Kaslow DC; Miller LH; Good MF
J Immunol; 1999 Jun; 162(12):7309-14. PubMed ID: 10358180
[TBL] [Abstract][Full Text] [Related]
25. Genetic diversity and immunogenicity of the merozoite surface protein 1 C-terminal 19-kDa fragment of Plasmodium ovale imported from Africa into China.
Xu Q; Liu S; Kassegne K; Yang B; Lu J; Sun Y; Zhong W; Zhang M; Liu Y; Zhu G; Cao J; Cheng Y
Parasit Vectors; 2021 Nov; 14(1):583. PubMed ID: 34819151
[TBL] [Abstract][Full Text] [Related]
26. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C
Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232
[TBL] [Abstract][Full Text] [Related]
27. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides.
Hirunpetcharat C; Wipasa J; Sakkhachornphop S; Nitkumhan T; Zheng YZ; Pichyangkul S; Krieg AM; Walsh DS; Heppner DG; Good MF
Vaccine; 2003 Jun; 21(21-22):2923-32. PubMed ID: 12798636
[TBL] [Abstract][Full Text] [Related]
28. Passive immunization with antibodies against three distinct epitopes on Plasmodium yoelii merozoite surface protein 1 suppresses parasitemia.
Spencer Valero LM; Ogun SA; Fleck SL; Ling IT; Scott-Finnigan TJ; Blackman MJ; Holder AA
Infect Immun; 1998 Aug; 66(8):3925-30. PubMed ID: 9673281
[TBL] [Abstract][Full Text] [Related]
29. Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP1
Rocha MV; Françoso KS; Lima LC; Camargo TM; Machado RLD; Costa FTM; Rénia L; Nosten F; Russell B; Rodrigues MM; Soares IS
Vaccine; 2017 Apr; 35(18):2463-2472. PubMed ID: 28341111
[TBL] [Abstract][Full Text] [Related]
30. Definition of T cell epitopes within the 19 kDa carboxylterminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) and their role in immunity to malaria.
Tian JH; Good MF; Hirunpetcharat C; Kumar S; Ling IT; Jackson D; Cooper J; Lukszo J; Coligan J; Ahlers J; Saul A; Berzofsky JA; Holder AA; Miller LH; Kaslow DC
Parasite Immunol; 1998 Jun; 20(6):263-78. PubMed ID: 9651928
[TBL] [Abstract][Full Text] [Related]
31. Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1.
Singh S; Kennedy MC; Long CA; Saul AJ; Miller LH; Stowers AW
Infect Immun; 2003 Dec; 71(12):6766-74. PubMed ID: 14638762
[TBL] [Abstract][Full Text] [Related]
32. Identification of T cell epitopes on the 33-kDa fragment of Plasmodium yoelii merozoite surface protein 1 and their antibody-independent protective role in immunity to blood stage malaria.
Wipasa J; Hirunpetcharat C; Mahakunkijcharoen Y; Xu H; Elliott S; Good MF
J Immunol; 2002 Jul; 169(2):944-51. PubMed ID: 12097400
[TBL] [Abstract][Full Text] [Related]
33. Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1.
Faber BW; Remarque EJ; Morgan WD; Kocken CH; Holder AA; Thomas AW
Infect Immun; 2007 Dec; 75(12):5947-55. PubMed ID: 17938224
[TBL] [Abstract][Full Text] [Related]
34. Effect of Plasmodium yoelii exposure on vaccination with the 19-kilodalton carboxyl terminus of merozoite surface protein 1 and vice versa and implications for the application of a human malaria vaccine.
Wipasa J; Xu H; Liu X; Hirunpetcharat C; Stowers A; Good MF
Infect Immun; 2009 Feb; 77(2):817-24. PubMed ID: 19015251
[TBL] [Abstract][Full Text] [Related]
35. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells.
Hirunpetcharat C; Tian JH; Kaslow DC; van Rooijen N; Kumar S; Berzofsky JA; Miller LH; Good MF
J Immunol; 1997 Oct; 159(7):3400-11. PubMed ID: 9317139
[TBL] [Abstract][Full Text] [Related]
36. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection.
Narum DL; Ogun SA; Thomas AW; Holder AA
Infect Immun; 2000 May; 68(5):2899-906. PubMed ID: 10768987
[TBL] [Abstract][Full Text] [Related]
37. Intranasal immunization with yeast-expressed 19 kD carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (yMSP119) induces protective immunity to blood stage malaria infection in mice.
Hirunpetcharat C; Stanisic D; Liu XQ; Vadolas J; Strugnell RA; Lee R; Miller LH; Kaslow DC; Good MF
Parasite Immunol; 1998 Sep; 20(9):413-20. PubMed ID: 9767608
[TBL] [Abstract][Full Text] [Related]
38. Immunization against malaria with a recombinant protein.
Ling IT; Ogun SA; Holder AA
Parasite Immunol; 1994 Feb; 16(2):63-7. PubMed ID: 8015856
[TBL] [Abstract][Full Text] [Related]
39. Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge.
Rénia L; Ling IT; Marussig M; Miltgen F; Holder AA; Mazier D
Infect Immun; 1997 Nov; 65(11):4419-23. PubMed ID: 9353014
[TBL] [Abstract][Full Text] [Related]
40. Crystal structure of a Fab complex formed with PfMSP1-19, the C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate.
Pizarro JC; Chitarra V; Verger D; Holm I; Pêtres S; Dartevelle S; Nato F; Longacre S; Bentley GA
J Mol Biol; 2003 May; 328(5):1091-103. PubMed ID: 12729744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
